Insmed (INSM) Cash & Equivalents (2010 - 2026)

Insmed's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $582.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 44.39% year-over-year to $582.2 million in Q1 2026; TTM through Mar 2026 was $582.2 million, a 44.39% increase from a year earlier, with the FY2025 full-year figure at $510.4 million, down 8.03% from the prior year.
• Cash & Equivalents rose to $582.2 million in Q1 2026 per INSM's latest filing, from $510.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q2 2025 and bottomed at $334.8 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $515.7 million (2022), against an average of $643.9 million.
• Across the five-year window, Cash & Equivalents slumped 55.18% in 2022 and soared 103.43% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $1.1 billion in 2022, then sank by 55.09% to $482.4 million in 2023, then climbed by 15.06% to $555.0 million in 2024, then dropped by 8.03% to $510.4 million in 2025, then grew by 14.06% to $582.2 million in 2026.
• Per Business Quant, the three latest INSM Cash & Equivalents figures stand at $582.2 million (Q1 2026), $510.4 million (Q4 2025), and $334.8 million (Q3 2025).